So where does NuvaRing® enter the game against this opponent?
HERE! The list below shows the threats presented by NuvaRing®
in the race to acquire new contraceptive users.
-
Monthly administration, not weekly
- Convenience
- Excellent cycle control
- Market clutter - noise about several new products
Other threats posed to Ortho EvraTM include:
- Transdermal adhesion issues
- MCO coverage
- Site reactions
- Possible side effects
- Concept resistance
- Overweight patients
- Low adoption in European countries
- Not truly low EE dose
